Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano Sells 1,541 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano sold 1,541 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $152.87, for a total transaction of $235,572.67. Following the transaction, the chief executive officer now directly owns 136,778 shares in the company, valued at approximately $20,909,252.86. This trade represents a 1.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Kyle Gano also recently made the following trade(s):

• On Wednesday, January 15th, Kyle Gano sold 65,000 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $141.50, for a total transaction of $9,197,500.00.

Neurocrine Biosciences Trading Up 1.5 %

NASDAQ:NBIX opened at $152.42 on Wednesday. Neurocrine Biosciences, Inc. has a 12 month low of $110.95 and a 12 month high of $157.98. The firm has a fifty day simple moving average of $137.92 and a 200-day simple moving average of $131.51. The company has a market capitalization of $15.43 billion, a P/E ratio of 40.86 and a beta of 0.33.

Analyst Ratings Changes

NBIX has been the topic of several research reports. Wedbush reissued an “outperform” rating and set a $148.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 16th. BMO Capital Markets cut their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a report on Thursday, October 17th. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a report on Friday, December 20th. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Finally, UBS Group lifted their price objective on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a report on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $166.85.

Institutional Investors Weigh In On Neurocrine Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in NBIX. State Street Corp lifted its stake in shares of Neurocrine Biosciences by 11.7% during the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock worth $593,186,000 after buying an additional 539,936 shares during the period. Jennison Associates LLC lifted its position in Neurocrine Biosciences by 145.1% during the fourth quarter. Jennison Associates LLC now owns 820,694 shares of the company’s stock valued at $112,025,000 after purchasing an additional 485,894 shares during the period. Los Angeles Capital Management LLC lifted its position in Neurocrine Biosciences by 639.6% during the third quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock valued at $48,479,000 after purchasing an additional 363,863 shares during the period. Impax Asset Management Group plc lifted its position in Neurocrine Biosciences by 207.8% during the fourth quarter. Impax Asset Management Group plc now owns 261,599 shares of the company’s stock valued at $35,708,000 after purchasing an additional 176,599 shares during the period. Finally, Braidwell LP lifted its position in Neurocrine Biosciences by 20.9% during the third quarter. Braidwell LP now owns 917,674 shares of the company’s stock valued at $105,734,000 after purchasing an additional 158,665 shares during the period. 92.59% of the stock is currently owned by institutional investors and hedge funds.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.